IFNL2 and COVID-19: IFNL2 had quite a different profile with roughly similar frequencies of healthy controls (48.6%) and HCV + plasma samples (53.8%) having detectable levels of this cytokine; this increased to 75% of the COVID-19 patients (Fig. 1B and Table 2).